# Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis

> **NCT00656747** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 1372 (actual)

## Conditions studied

- Chronic Bronchitis

## Interventions

- **DRUG:** Avelox (Moxifloxacin, BAY12-8039)
- **DRUG:** Amoxicillin clavulanic acid

## Key facts

- **NCT ID:** NCT00656747
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 1372 (ACTUAL)
- **Last updated:** 2014-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00656747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00656747, "Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00656747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*